These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 9679910

  • 1. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K, Berger M, Ball R.
    J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
    [No Abstract] [Full Text] [Related]

  • 2. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A.
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [Abstract] [Full Text] [Related]

  • 3. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR, Zietman AL, Finkelstein JS, Wu CL.
    N Engl J Med; 2011 May 26; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract] [Full Text] [Related]

  • 4. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 5. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A.
    Int J Urol; 2006 Jan 15; 13(1):87-8. PubMed ID: 16448441
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H, Kontani K, Okaneya T, Yoneyama T.
    Hinyokika Kiyo; 1997 Jun 15; 43(6):421-3. PubMed ID: 9250492
    [Abstract] [Full Text] [Related]

  • 8. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R, Renneberg H, Lübben G, Kienle E, Tunn UW.
    Eur Urol; 1999 Jun 15; 35 Suppl 1():27-31. PubMed ID: 10081700
    [Abstract] [Full Text] [Related]

  • 9. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N, Klotz L, Crook J, Goldenberg SL.
    Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527
    [Abstract] [Full Text] [Related]

  • 10. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ, Oh WK.
    Urology; 2006 May 01; 67(5):1084.e15-7. PubMed ID: 16698377
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec 01; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

  • 13. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I.
    BJU Int; 2008 May 01; 101(9):1096-100. PubMed ID: 18190637
    [Abstract] [Full Text] [Related]

  • 14. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM, Rose AL, Higano C.
    J Urol; 2003 Nov 01; 170(5):1808-11. PubMed ID: 14532781
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB.
    J Urol; 2001 May 01; 165(5):1585-9. PubMed ID: 11342922
    [Abstract] [Full Text] [Related]

  • 17. Hormonal treatment of prostate cancer.
    Garnick MB.
    N Engl J Med; 1999 Mar 11; 340(10):812-3. PubMed ID: 10075531
    [No Abstract] [Full Text] [Related]

  • 18. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
    Pickles T, Agranovich A, Berthelet E, Duncan GG, Keyes M, Kwan W, McKenzie MR, Morris WJ, British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative.
    Cancer; 2002 Jan 15; 94(2):362-7. PubMed ID: 11900222
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S, Simon JM, Mazeron JJ.
    Bull Cancer; 2009 Mar 15; 96(3):261-70. PubMed ID: 19318304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.